Atlas Trials

Study of BTK Inhibitor, Ibrutinib in Combination With Carfilzomib in Subjects With Relapsed and Refractory Multiple Myeloma

Clinical trial NCT01962792 · COMPLETED

Trial details

NCT number
NCT01962792
Sponsor
Pharmacyclics LLC.
Status
COMPLETED
Phase
Phase 1, Phase 2
Study type
INTERVENTIONAL
Multiple Myeloma
Start date
2013-12-01
Primary completion
2019-03-01
Enrollment
84

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.